Growth inhibitory effect of Cucurbitacin E on breast cancer cells

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 9, 2013, Pages 1799-1805

  Lan, Tian ^a,b   Wang, Linling ^b   Xu, Qian ^a   Liu, Weiguo ^a   Jin, Hongchuan ^b   Mao, Weimin ^a   Wang, Xian ^b   Wang, Xiaojia ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Cucurbitacin E

Indexed keywords

ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASPASE 3; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CISPLATIN; CUCURBITACIN E; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TRITERPENE;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

APOPTOSIS; BREAST CANCER; CUCURBITACIN E;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRITERPENES;

EID: 84885438579     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chen JC, Chiu MH, Nie RL, Cordell GA and Qiu SX. Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 2005; 22: 386-399.
2. Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, Wu Y, Song Y, Luo J, Pang X, Yi Z and Liu M. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STA-T3 signaling pathway. Carcinogenesis 2010; 31: 2097-2104.
3. Ayyad SE, Abdel-Lateff A, Alarif WM, Patacchioli FR, Badria FA and Ezmirly ST. In vitro and in vivo study of cucurbitacins-type triterpene glucoside from Citrullus colocynthis growing in Saudi Arabia against hepatocellular carcinoma. Environ Toxicol Pharmacol 2012; 33: 245-251.
4. Sun C, Zhang M, Shan X, Zhou X, Yang J, Wang Y, Li-Ling J and Deng Y. Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol 2010; 136: 603-610.
5. He Y, Korboukh I, Jin J and Huang J. Targeting protein lysine methylation and demethylation in cancers. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 70-79.
6. Wang Y, Ding L, Wang X, Zhang J, Han W, Feng L, Sun J, Jin H and Wang XJ. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am J Transl Res 2012; 4: 44-51.
7. Alghasham AA. Cucurbitacins - a promising target for cancer therapy. Int J Health Sci (Qassim) 2013; 7: 77-89.
8. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D and Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005; 24: 3236-3245.
9. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW and Koeffler HP. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-5884.
10. Lopez-Haber C and Kazanietz MG. Cucurbitacin I inhibits Rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of Janus tyrosine kinase 2 and P-Rex1. Mol Pharmacol 2013; 83: 1141-1154.
11. Ding N, Yamashita U, Matsuoka H, Sugiura T, Tsukada J, Noguchi J and Yoshida Y. Apoptosis induction through proteasome inhibitory activity of cucurbitacin D in human T-cell leukemia. Cancer 2011; 117: 2735-2746.
12. Promkan M, Dakeng S, Chakrabarty S, Bogler O and Patmasiriwat P. The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells. PLoS One 2013; 8: e55732.
13. Duncan KL, Duncan MD, Alley MC and Sausville EA. Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol 1996; 52: 1553-1560.
14. Ren S, Ouyang DY, Saltis M, Xu LH, Zha QB, Cai JY and He XH. Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human pros tate cancer cells through induction of actin aggregation and cofilin-actin rod formation. Cancer Chemother Pharmacol 2012; 70: 415-424.
15. Chen X, Bao J, Guo J, Ding Q, Lu J, Huang M and Wang Y. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs 2012; 23: 777-787.
16. Yin D, Wakimoto N, Xing H, Lu D, Huynh T, Wang X, Black KL and Koeffler HP. Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer 2008; 123: 1364-1375.
17. Smit HF, van den Berg AJ, Kroes BH, Beukelman CJ, Quarles van Ufford HC, van Dijk H and Labadie RP. Inhibition of T-lymphocyte proliferation by cucurbitacins from Picrorhiza scrophulariaeflora. J Nat Prod 2000; 63: 1300-1302.
18. Sadzuka Y, Hatakeyama H and Sonobe T. Enhancement of doxorubicin concentration in the M5076 ovarian sarcoma cells by cucurbitacin E co-treatment. Int J Pharm 2010; 383: 186-191.
19. Liu T, Zhang M, Zhang H, Sun C, Yang X, Deng Y and Ji W. Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 2008; 587: 78-84.
20. Henrich CJ, Thomas CL, Brooks AD, Booth NL, Lowery EM, Pompei RJ, McMahon JB and Sayers TJ. Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis. Apoptosis 2012; 17: 79-89.